The International Society for Pharmaceutical Engineering (ISPE)
has announced ISPE AI (TM), which includes the launch of the ISPE
Community of Practice (CoP) on Artificial Intelligence (AI).
NORTH
BETHESDA, Md., Aug. 6, 2024
/PRNewswire-PRWeb/ -- The International Society for
Pharmaceutical Engineering (ISPE) has announced
ISPE AI (TM), a significant initiative aimed at aiding the
pharmaceutical industry in realizing the potential of artificial
intelligence (AI). The initiative will include a multifaceted
approach to supporting the industry in AI readiness, beginning with
the launch of the ISPE Community of Practice
(CoP) on Artificial Intelligence (AI). Over
time, ISPE will also provide new ISPE
Guidance Documents, additional conference sessions, new
training courses, and more, which focus on AI-related planning and
implementation.
"Recent advances in AI have brought attention to this rapidly
accelerating technological innovation. The launch of this AI
Community of Practice is a testament to ISPE's commitment to
shaping the future of the pharmaceutical industry," said
Thomas Hartman, President and CEO of
ISPE. "We are acutely aware of the needs and interest areas of our
members and recognize the importance of supporting the
pharmaceutical industry in the responsible advancement of AI."
ISPE's AI CoP is available for ISPE members to join, effective
immediately. The new CoP joins ISPE's existing array of 22 Global
Technical CoPs, including the recently announced Sustainability
CoP. Each ISPE Global CoP has a Steering Committee, comprised of
subject matter experts who specialize in each respective CoP topic
area. CoP Steering Committees collaborate on ISPE content
generation plans, which may include ISPE Guidance Documents,
Pharmaceutical Engineering® magazine articles, webinars,
educational materials, and conference content.
The new AI CoP Steering Committee will address essential areas
such as the regulatory aspects of AI, guidance on applications of
AI throughout the pharmaceutical lifecycle, organizational
preparedness for implementation of AI, benchmarking, workforce
education and skills development, and organizational impacts. The
new CoP will also build upon the endeavors of the ISPE GAMP®
Artificial Intelligence/Machine Learning Special Interest Group,
and ISPE's Pharma 4.0™ initiatives, which have been actively
contributing to the industry's adoption of digitalization
strategies and AI/machine learning (ML) technologies.
"As a trusted leader in the pharmaceutical industry, ISPE is
uniquely positioned to support this increased focus into the
critical area of AI/ML. As with all ISPE CoPs, our AI CoP will aim
to identify and provide best practices, interface with regulatory
authorities, and share lessons learned as well as emerging case
studies to inform effective AI/ML strategy and implementation,"
said Ben Stevens, Director of CMC
Policy and Advocacy with GSK and Chair of the newly formed AI
CoP.
Existing ISPE members are invited to join the AI CoP by
selecting "Artificial Intelligence" in the Communities tab in their
ISPE profiles. To view the list of existing CoPs, visit
ISPE.org/CoP. To become an ISPE member, visit ISPE.org/join.
About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is
a global nonprofit association serving its members through leading
scientific, technical, and regulatory advancement across the entire
pharmaceutical lifecycle. The 22,000+ members of ISPE provide
solutions to complex pharmaceutical industry challenges through
innovation, member and workforce development, and technical,
regulatory, and compliance collaborations in more than 120
countries worldwide. Founded in 1980, ISPE has its worldwide
headquarters and training center in North
Bethesda, Maryland, USA, and its operations center in
Tampa, Florida, USA. For more
information, visit ISPE.org.
Media Contact
Katie LeChase, ISPE,
+1-360-718-9771, KLeChase@ispe.org
View original
content:https://www.prweb.com/releases/ispe-announces-ispe-ai-tm-an-artificial-intelligence-initiative-302215697.html
SOURCE ISPE